Affiliation:
1. Engineering Research Center of Cell and Therapeutic Antibody Medicine, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China
Abstract
Recruitment and accumulation of reactive astrocytes around senile plaques are common pathological features of Alzheimer’s disease (AD), with unclear mechanisms. Chemerin, an adipokine implicated in neuroinflammation, acts through its receptor, chemokine-like receptor 1 (CMKLR1), which also functions as a receptor for amyloid β (Aβ). The impact of the chemerin/CMKLR1 axis on astrocyte migration towards Aβ plaques is unknown. Here we investigated the effect of CMKLR1 on astrocyte migration around Aβ deposition in APP/PS1 mice with Cmklr1 knockout (APP/PS1-Cmklr1−/−). CMKLR1-expressed astrocytes were upregulated in the cortices and hippocampi of 9-month-old APP/PS1 mice. Chemerin mainly co-localized with neurons, and its expression was reduced in the brains of APP/PS1 mice, compared to WT mice. CMKLR1 deficiency decreased astrocyte colocalization with Aβ plaques in APP/PS1-Cmklr1−/− mice, compared to APP/PS1 mice. Activation of the chemerin/CMKLR1 axis promoted the migration of primary cultured astrocytes and U251 cells, and reduced astrocyte clustering induced by Aβ42. Mechanistic studies revealed that chemerin/CMKLR1 activation induced STING phosphorylation. Deletion of STING attenuated the promotion of the chemerin/CMKLR1 axis relative to astrocyte migration and abolished the inhibitory effect of chemerin on Aβ42-induced astrocyte clustering. These findings suggest the involvement of the chemerin/CMKLR1/STING pathway in the regulation of astrocyte migration and recruitment to Aβ plaques/Aβ42.
Funder
Natural Science Foundation of Shanghai
National Natural Science Foundation of China
Reference60 articles.
1. Alzheimer’s disease;Querfurth;N. Engl. J. Med.,2010
2. Inflammation in neurodegenerative disease—A double-edged sword;Mucke;Neuron,2002
3. 2021 marks a new era for Alzheimer’s therapeutics;Kantarci;Lancet Neurol.,2022
4. FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm;Mullard;Nat. Rev. Drug Discov.,2021
5. Lecanemab in Early Alzheimer’s Disease;Swanson;N. Engl. J. Med.,2023